IceCure Medical (ICCM)
(Real Time Quote from BATS)
$0.78 USD
+0.08 (11.96%)
Updated Jul 23, 2024 03:54 PM ET
After-Market: $0.83 +0.05 (6.41%) 4:14 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.78 USD
+0.08 (11.96%)
Updated Jul 23, 2024 03:54 PM ET
After-Market: $0.83 +0.05 (6.41%) 4:14 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Zacks News
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
by Zacks Equity Research
IceCure's (ICCM) ProSense cryoablation system demonstrated a 100% complete ablation rate for breast cancer per a study published in "Cancers."
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
by Zacks Equity Research
IceCure Medical's (ICCM) XSense Cryoablation System receives FDA approval, marking a pivotal step in minimally-invasive tumor treatment across multiple medical fields
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Doximity (DOCS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 25% and 1.37%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ReWalk Robotics (LFWD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ReWalk (LFWD) delivered earnings and revenue surprises of -4.29% and 4.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Oncology Institute, Inc. (TOI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
The Oncology Institute (TOI) delivered earnings and revenue surprises of -83.33% and 0.53%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
DocGo Inc. (DCGO) Matches Q1 Earnings Estimates
by Zacks Equity Research
Motion Acquisition (DCGO) delivered earnings and revenue surprises of 0% and 3.63%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ascend Wellness Holdings, Inc. (AAWH) delivered earnings and revenue surprises of -80% and 1.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revvity (RVTY) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Revvity (RVTY) delivered earnings and revenue surprises of 4.26% and 0.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA
by Zacks Equity Research
IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 0% and 65.58%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of -29.17% and 73.60%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Nutex Health Inc. (NUTX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nutex Health Inc. (NUTX) delivered earnings and revenue surprises of 0% and 5.34%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 11.11% and 25.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
LumiraDx Limited (LMDX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of 6.67% and 17.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MDxHealth SA Sponsored ADR (MDXH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MDxHealth SA Sponsored ADR (MDXH) delivered earnings and revenue surprises of 87.50% and 6.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. (CODX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Co-Diagnostics, Inc. (CODX) delivered earnings and revenue surprises of 13.04% and 45.27%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
The Beauty Health Company (SKIN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Beauty Health Company (SKIN) delivered earnings and revenue surprises of -100% and 3.90%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Apollo Medical Holdings, Inc. (AMEH) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Apollo Medical Holdings, Inc. (AMEH) delivered earnings and revenue surprises of 20% and 1.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
1,000% Move in a Day: Medical Stock Soars on Positive Data
by Andrew Rocco
IceCure Medical, a little-known medical device company surged in after-hours trading Monday. IceCure's Prosense technology proved to be a safe and effective treatment for cancerous kidney tumors.